INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Total Non-Current Liabilities History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹2.29 Cr | ₹3.59 Cr | ₹2.09 Cr | ₹4.07 Cr | ₹3.92 Cr |
What is the latest Total Non-Current Liabilities ratio of INDO US BIOTECH ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹2.29 Cr |
| Mar2024 | ₹3.59 Cr |
| Mar2023 | ₹2.09 Cr |
| Mar2022 | ₹4.07 Cr |
| Mar2021 | ₹3.92 Cr |
How is Total Non-Current Liabilities of INDO US BIOTECH Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹2.29 Cr | -36.14 | |
| Mar2024 | ₹3.59 Cr | 71.41 | |
| Mar2023 | ₹2.09 Cr | -48.61 | |
| Mar2022 | ₹4.07 Cr | 3.96 | |
| Mar2021 | ₹3.92 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹249.9 Cr | -7.3% | -1.9% | -50% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹14,114.2 Cr | 7.1% | 7.2% | -31.1% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹5,474.2 Cr | 3.7% | 0.4% | 20.3% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,884.7 Cr | 0.4% | -8.7% | -23.1% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,193.6 Cr | -3.5% | -7.1% | -27.2% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹494.3 Cr | 7.6% | -2.2% | 21.2% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -7.3% |
-1.9% |
-50% |
| SENSEX | 1% |
2.5% |
6.5% |
You may also like the below Video Courses